Finance

Lists
CAPR:NASDAQ
Capricor Therapeutics Inc
$8.37
+0.84%
(+0.070) 1D
$8.37
0.00% (0.00)
After hours
Closed: Sep 11, 4:00:01 PM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for CAPR...
Open
$8.32
High
$8.67
Low
$8.26
Mkt. cap
486.62M
Avg. vol.
9.97M
Volume
2.07M
52-wk high
$40.37
52-wk low
$2.96
EPS
-$2.45
Beta
0.72
Shares outstanding
58.14M
No. of employees
231
Open
$8.32
High
$8.67
Low
$8.26
Mkt. cap
486.62M
Avg. vol.
9.97M
Volume
2.07M
52-wk high
$40.37
52-wk low
$2.96
EPS
-$2.45
Beta
0.72
Shares outstanding
58.14M
No. of employees
231
News stories
From web sources and news partners
About Capricor Therapeutics Inc
CEOLinda Marban
Employees231
Founded2005
Headquarters-
SectorBiotechnology
Websitecapricor.com
Analyst ratings
Based on 10 analysts giving stock ratings to CAPR in the past 3 months
Buy
Buy
3
Hold
7
Sell
0
12-month forecast
Based on 10 Wall Street analysts offering 12 month price targets for CAPR in the last 3 months.
Highest
Current $8.37
$54.00 (+545.16%)
Average
$23.80 (+184.35%)
Lowest
$5.00 (-40.26%)
Analyst
Recommendation
Action
Price target
Projected
Date
Edward Tenthoff
Piper Sandler
Buy
Upgraded
$25.00
+198.7%
09/01/2026
Boobalan Pachaiyappan
Roth MKM
Hold
Maintained
$7.00
-16.4%
08/25/2026
Leland Gershell
Oppenheimer
Buy
Upgraded
$54.00
+545.2%
08/25/2026
Joseph Pantginis
H.C. Wainwright
Hold
Maintained
-
-
08/24/2026
Jason McCarthy
Maxim Group
Hold
Maintained
-
-
08/14/2026
Kristen Kluska
Cantor Fitzgerald
Buy
Upgraded
$28.00
+234.5%
08/14/2026
Catherine Novack
JonesTrading
Hold
Downgraded
-
-
07/30/2026
Madison Elsaadi
B. Riley Securities
Hold
Downgraded
$5.00
-40.3%
07/31/2026
Rick Bienkowski
Ladenburg Thalmann & Co.
Hold
Downgraded
-
-
07/30/2026
Matthew Venezia
Alliance Global Partners
Hold
Maintained
-
-
07/30/2026
Unknown Analyst
B. Riley Securities
Buy
Maintained
$63.00
+652.7%
07/27/2026
Unknown Analyst
Alliance Global Partners
Buy
Reiterated
$51.00
+509.3%
03/13/2026
Last report
Aug 13, 2026
Fiscal period
Q2 2026
EPS / Est. (USD)
-$0.70 / -$0.58
-21.62%miss
Revenue / Est. (USD)
- / 0.00
Fiscal Q2 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Revenue
-
-
-
-
Cost of goods sold
20.36M
23.13M
27.38M
28.87M
Cost of revenue
20.36M
23.13M
27.38M
28.87M
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
5.92M
6.02M
9.40M
14.08M
Operating expense
5.92M
6.02M
9.40M
14.08M
Total operating expenses
26.28M
29.16M
36.77M
42.95M
Operating income
-26.28M
-29.16M
-36.77M
-42.95M
Other non operating income
6.74K
11.20K
8.14K
2.27K
EBT including unusual items
-24.57M
-30.17M
-33.94M
-40.73M
EBT excluding unusual items
-24.56M
-30.17M
-33.86M
-40.73M
Income tax expense
-
1.60K
-
1.60K
Effective tax rate
-
-0.01%
-
-
Other operating expenses
-
-
-
-
Net income
-24.57M
-30.17M
-33.94M
-40.73M
Net profit margin
-
-
-
-
Earnings per share
-0.54
-0.62
-0.59
-0.70
Interest and investment income
1.71M
2.02M
2.90M
2.21M
Interest expense
-
-3.05M
-
-
Net interest expenses
1.71M
-1.02M
2.90M
2.21M
Depreciation and amortization charges
-
-
-
-
EBITDA
-25.79M
-28.65M
-36.24M
-42.38M
Gain or loss from assets sale
6.85K
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google apps